US Patent 10,251,895: Claim Scope, Duobrii Protection, and Generic Entry Risks

US Patent No. 10,251,895 protects a narrowly defined topical fixed-dose combination of halobetasol propionate and tazarotene. The independent claim requires exact active-ingredient concentrations, an oil-in-water emulsion, and an oil phase containing both diethyl sebacate and light mineral oil. The patent is directed to the composition itself, not merely to the use of either ingredient for psoriasis.

The claims closely track the formulation used in Duobrii lotion, approved by the FDA for plaque psoriasis in adults. The strongest infringement risk applies to a product reproducing the claimed 0.01% halobetasol propionate and 0.045% tazarotene concentrations in the specified emulsion platform. A generic product using materially different oils, a different dosage form, or different concentrations may avoid literal infringement, although other related patents may remain relevant. (U.S. Patent No. 10,251,895, 2019; FDA, 2023a).

What does US Patent 10,251,895 protect?

The patent protects a topical psoriasis composition with six material limitations in claim 1:

Claim element	Required scope
Therapeutic indication	Treating psoriasis
Active ingredients	Halobetasol propionate and tazarotene, with the active ingredients “consisting of” those two ingredients
Halobetasol concentration	Exactly 0.01% by weight
Tazarotene concentration	Exactly 0.045% by weight
Dosage form	Oil-in-water emulsion
Oil phase	Liquid oil component liquid at 22°C and consisting of diethyl sebacate and light mineral oil
Functional result	Capability of providing synergistic efficacy and synergistic reduction of itching, burning, or stinging

Claim 1 does not require a particular commercial package, brand name, preservative system, fragrance, pH, viscosity, or manufacturing process. Those features may affect infringement under the composition claim only if they alter one of the expressly claimed limitations.

The term “active ingredients consisting of” is important. It excludes a composition whose active-ingredient group contains another pharmacologically active compound. It does not necessarily exclude inactive excipients, preservatives, antioxidants, pH adjusters, rheology modifiers, or other carrier components.

How narrow is claim 1?

Claim 1 is narrow in formulation architecture but potentially broad in excipient detail.

The claim requires the following combination:

Two specified actives.
Exact labeled strengths.
An oil-in-water emulsion.
An oil phase containing a liquid oil component.
The liquid oil component consisting of diethyl sebacate and light mineral oil.
The claimed synergistic efficacy and tolerability result.

The claim does not require the two actives to be dissolved in the liquid oil component. That requirement appears in dependent claim 2. A competitor could therefore face claim 1 even if one or both actives are partly dispersed rather than fully dissolved, provided the remaining limitations are met.

The phrase “consists of diethyl sebacate and light mineral oil” creates a potential prosecution-history and claim-construction issue. At its broadest, it means the claimed liquid oil component contains those two oils and no additional liquid-oil constituent. It does not necessarily mean that the entire oil phase contains only those two substances, because the claim distinguishes the “liquid oil component” from the broader “oil phase.” The precise scope depends on the patent specification and prosecution history.

What do claims 2 through 6 add?

What formulation is covered by claim 2?

Claim 2 requires both halobetasol propionate and tazarotene to be dissolved in the liquid oil component of the emulsion.

This limitation is narrower than claim 1 and creates a formulation-performance distinction. A product in which the active ingredients are fully dissolved in the diethyl sebacate and light mineral oil phase is more exposed under claim 2. A product with one active suspended in the aqueous phase, present as undissolved crystals, or incorporated through a different delivery system may avoid literal infringement of claim 2 while remaining potentially subject to claim 1.

Does the patent cover both lotions and creams?

Yes. Claims 3 and 4 expressly identify both dosage forms:

Claim	Dosage form
Claim 3	Lotion
Claim 4	Cream

The use of “lotion” and “cream” does not necessarily create a complete technical boundary. Courts generally evaluate the formulation’s composition and ordinary meaning in context. A product marketed as a cream but having the claimed oil-in-water composition could still present claim 4 exposure. A lotion that satisfies claim 1 and claim 2 would fall within claim 3.

Duobrii is marketed as a lotion. The express cream claim expands the patent’s reach beyond the branded dosage form and may be relevant to an alternative generic presentation. (FDA, 2023a).

What carbomer system is covered by claim 5?

Claim 5 requires the aqueous phase to contain:

Carbomer copolymer type B; and
Carbomer homopolymer type A.

The claim does not require the specific concentrations later stated in claim 6. A formulation containing both polymer classes may therefore fall within claim 5 even if the amounts differ from the narrower ranges in claim 6.

The identity of the polymer grades matters. “Carbomer” is a broad excipient category. A product containing a different carbomer grade, a crosslinked acrylic acid polymer outside the claimed classifications, or a non-carbomer thickener may avoid literal infringement. Equivalence arguments remain possible but would depend on prosecution history and technical evidence.

What exact composition is covered by claim 6?

Claim 6 adds quantitative ranges:

Component	Claimed concentration
Diethyl sebacate	2.5% to 3.5% by weight
Light mineral oil	7.5% to 8.5% by weight
Carbomer copolymer type B	0.3% to 0.5% by weight
Carbomer homopolymer type A	0.5% to 0.7% by weight

A formulation within those ranges, containing the claim 1 actives and satisfying the preceding emulsion and dissolution limitations, has the highest literal infringement exposure under this patent.

The ranges are open at the endpoints unless the patent or prosecution history indicates otherwise. A composition at exactly 2.5% diethyl sebacate or exactly 8.5% light mineral oil would ordinarily fall within the stated range.

Does the patent cover the Duobrii formulation?

The claims are directed to the same active ingredients and strengths used in Duobrii:

Halobetasol propionate: 0.01%
Tazarotene: 0.045%
Dosage form: lotion
Emulsion type: oil-in-water

The FDA label describes Duobrii as a topical lotion containing halobetasol propionate and tazarotene at those concentrations. The claim language therefore has a direct commercial read-through to the approved product, subject to confirmation of the complete excipient composition and the technical meaning of the liquid-oil limitation. (FDA, 2023a).

The supplied claims do not establish whether every commercial batch satisfies claim 6. That question depends on the quantitative composition and excipient grades. Claim 1 does not require the carbomer combination or the concentration ranges in claim 6.

What is the patent’s functional “synergy” limitation?

Claim 1 requires that the composition be “capable of providing synergistic efficacy and synergistic reduction” of at least one adverse event: itching, burning, or stinging.

This language has two effects.

First, it ties the claimed composition to a functional property rather than merely to its ingredients. The patent holder may argue that the specified formulation is patentable because the combination produces more psoriasis efficacy, better tolerability, or both than would be expected from the individual components.

Second, the limitation may create proof issues in litigation. A composition does not necessarily avoid the claim merely because a particular patient does not experience synergy. The wording “capable of providing” generally focuses on the composition’s capability, while “synergistic” may require a defined comparison and an evidentiary showing.

The patent specification and prosecution history would be important in determining whether synergy means:

Statistical superiority over halobetasol propionate alone;
Statistical superiority over tazarotene alone;
A more-than-additive pharmacodynamic effect;
Improved efficacy with reduced adverse events; or
A specific clinical endpoint or study design.

A generic applicant could challenge the limitation for indefiniteness, lack of written description, enablement, or lack of demonstrated synergy. The patent holder could respond that the specification identifies the formulation and supporting clinical or experimental data sufficient to establish the claimed property.

What patents protect Duobrii and related halobetasol-tazarotene products?

US Patent 10,251,895 should be evaluated as part of a family and Orange Book portfolio rather than in isolation. Public patent records identify multiple US patents associated with the halobetasol-tazarotene combination, including patents directed to composition, formulation, and methods of treatment. The applicable portfolio can change through continuation practice, patent-term adjustments, terminal disclaimers, and Orange Book updates.

Protection category	Relevance to Duobrii or a follow-on product
Fixed-dose composition	Protects the specified halobetasol-tazarotene combination
Emulsion formulation	Protects oil-in-water architecture and selected excipients
Dissolution system	Protects dissolution of the actives in the liquid oil phase
Dosage form	Covers lotion and cream embodiments
Method of treatment	May cover treating plaque psoriasis with the combination
Manufacturing process	May cover preparation, mixing, homogenization, or active incorporation
Clinical or tolerability result	May support validity and infringement arguments concerning synergy

The patent number alone does not establish the complete Orange Book listing. Orange Book status must be determined from the FDA’s current patent listing for the approved product and its associated reference-listed drug. (FDA, 2024).

What is the Orange Book status of US Patent 10,251,895?

A patent is relevant to an abbreviated new drug application only if it is listed for the applicable reference-listed drug and satisfies FDA listing requirements. A patent may be commercially important without being listed in the Orange Book, particularly if it covers a manufacturing process or a claim that is not directed to the drug substance, drug product, or approved method of use.

For Duobrii, the relevant regulatory questions are:

Whether US 10,251,895 is listed against the reference-listed drug.
Whether the listing is for the drug product, method of use, or another category.
The listed expiration date.
Whether the patent has a pediatric extension, patent-term adjustment, or terminal disclaimer.
Whether the listed claims correspond to the approved lotion.

The FDA Orange Book, not a third-party patent database, controls the operational significance of the listing for an ANDA applicant. (FDA, 2024).

When does US Patent 10,251,895 lose exclusivity?

The patent’s enforceable term is governed by 35 U.S.C. § 154 and normally runs 20 years from the earliest effective nonprovisional US filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. The issue date, April 9, 2019, does not determine the expiration date. (35 U.S.C. § 154).

The precise expiration date should be taken from the USPTO patent record and any Orange Book entry. The regulatory exclusivity period is separate from patent exclusivity:

Exclusivity type	Effect
Patent term	Bars or exposes an accused product to infringement liability
New-drug exclusivity	Controls certain FDA approval timing
Three-year exclusivity	Can delay approval of some applications relying on new clinical investigations
Pediatric extension	Can add six months to qualifying exclusivity periods
Orphan exclusivity	Generally not applicable to a standard plaque-psoriasis product

Duobrii was approved in 2019. Its approval did not itself determine the expiration of US 10,251,895 or the entire patent family. (FDA, 2019).

What Paragraph IV challenges could target this patent?

An ANDA applicant seeking approval before patent expiration could submit a Paragraph IV certification if it contends that the patent is invalid, unenforceable, or not infringed. The most plausible challenge theories would be:

Noninfringement

A proposed product could avoid one or more limitations by using:

Different active concentrations;
A non-oil-in-water dosage form;
A different liquid oil;
Diethyl sebacate or mineral oil outside the claimed liquid-oil definition;
A different carbomer system;
A suspension rather than a solution in the liquid oil phase; or
A formulation that lacks the claimed capability of synergistic efficacy and adverse-event reduction.

Invalidity based on obviousness

An ANDA filer could combine prior art disclosing:

Halobetasol propionate for psoriasis;
Tazarotene for psoriasis;
Fixed-dose topical steroid-retinoid combinations;
Oil-in-water emulsions;
Diethyl sebacate and mineral oil as topical solvents or emollients; and
Carbomer thickener systems.

The principal defense would be unexpected results, particularly reduced itching, burning, or stinging combined with improved efficacy. The strength of that defense depends on the quality of comparative data, the closest prior art, the claimed ranges, and whether the results are commensurate with the full claim scope.

Written description and enablement

The exact concentrations and excipient architecture are relatively concrete. A challenge would be stronger if the patent specification disclosed only limited examples while claiming a broad range of formulations or broad synergy outcomes.

Indefiniteness

Potential issues include the meaning of “synergistic,” “capable of providing,” “light mineral oil,” and “consists of” in the context of the liquid oil component. Objective test methods and specification definitions would materially affect this analysis.

How strong is the patent estate?

US 10,251,895 has moderate-to-strong formulation relevance for a Duobrii-like product because claim 1 combines precise active strengths with a distinctive emulsion and oil system. Its principal weakness is claim narrowness. A technically competent generic developer may be able to design around the oil component, dissolution requirement, carbomer system, or dosage form.

The estate is stronger if related patents separately cover:

The same active combination without the specific oil limitations;
Treatment methods for plaque psoriasis;
The commercial lotion formulation;
Manufacturing steps that are difficult to replace without affecting stability or bioavailability; and
Additional formulation attributes listed for the reference product.

The estate is weaker if the principal enforceable protection is limited to the exact claim set supplied and the prosecution history narrowed “synergy” or the liquid-oil limitation.

What generic launch scenarios exist?

Scenario	Likely exposure
Exact 0.01%/0.045% lotion using the same oil system	High literal-infringement risk
Same strengths, different oil replacing diethyl sebacate	Potential design-around, subject to related patents
Same actives in a cream	Claim 4 risk; additional formulation patents must be checked
Same strengths with actives not dissolved in the liquid oil	Claim 2 may be avoided; claim 1 remains relevant
Different strengths	Claim 1 literal infringement may be avoided, but approval and clinical equivalence become separate issues
Non-emulsion vehicle	Likely avoids claim 1, subject to other claims
Product with another active ingredient	Potentially outside “active ingredients consisting of,” subject to other patents

For an ANDA, the commercial path depends on the Orange Book patent listings, the applicant’s certifications, any 30-month stay triggered by timely patent litigation, and the outcome of settlement or district-court proceedings. A first Paragraph IV filer may also qualify for 180-day generic exclusivity if statutory conditions are satisfied. (21 U.S.C. § 355; FDA, 2024).

What litigation and settlement risks affect the product?

The relevant litigation risk is not limited to infringement. A branded-product sponsor could assert the listed patent after receiving a Paragraph IV notice. The case may involve:

Claim construction concerning “consists of”;
Whether the accused oil is liquid at 22°C;
Whether the actives are dissolved in the liquid-oil phase;
Whether the accused formulation is a lotion or cream;
Whether the composition is capable of synergistic efficacy and improved tolerability;
Validity over combination prior art; and
The effect of any prosecution disclaimer.

A settlement could permit a generic launch before the latest patent expiry, but the terms may remain confidential or be disclosed only in summary form. No specific settlement conclusion should be inferred from the existence of the patent alone.

How does this patent compare with method-of-use and manufacturing patents?

US 10,251,895 is primarily a product-composition patent. It differs from method-of-use patents, which generally require the accused product to be labeled or used for the claimed psoriasis indication. It also differs from manufacturing patents, which may be infringed by the production method even if the final composition is redesigned.

Composition patents are often more commercially powerful when the claims read directly on the approved product. Method patents can be easier to avoid through a carve-out label, although FDA labeling restrictions and induced-infringement theories may limit that strategy. Manufacturing patents matter most when the patented process is necessary to achieve the required solubility, stability, particle size, or emulsion structure.

Key Takeaways

US Patent 10,251,895 claims a narrow fixed-dose topical combination of 0.01% halobetasol propionate and 0.045% tazarotene.
Claim 1 requires an oil-in-water emulsion with a liquid oil component consisting of diethyl sebacate and light mineral oil.
Claims 2 through 6 add dissolution, lotion, cream, carbomer, and concentration limitations.
The claims closely correspond to Duobrii’s active ingredients and strengths.
The synergy limitation may support patentability but could generate claim-construction and evidentiary disputes.
A generic using the same strengths and the same oil system faces the highest infringement risk.
A product using different oils, a non-emulsion vehicle, different concentrations, or a different active-delivery approach may have a credible design-around position.
Orange Book listing, continuation patents, method patents, terminal disclaimers, patent-term adjustment, and Paragraph IV litigation determine the actual launch barrier.
The patent’s issue date does not establish expiration. The enforceable term must be determined from the USPTO and FDA records.

FAQs

Is US 10,251,895 a patent on halobetasol propionate alone?

No. It claims a combination containing halobetasol propionate and tazarotene at specified concentrations in a defined topical emulsion.

Can a generic use tazarotene at a different concentration?

A materially different tazarotene concentration would generally avoid literal infringement of claim 1, which specifies 0.045% by weight. Other patents, regulatory requirements, or equivalents arguments could still affect the product.

Does a cream infringe a patent directed to Duobrii lotion?

Potentially. Claim 4 expressly covers a cream, provided the formulation satisfies the other inherited limitations from claims 1 and 2.

Does replacing light mineral oil eliminate infringement?

It may avoid literal infringement of the liquid-oil limitation, but the result depends on whether the replacement is legally equivalent and whether related patents cover the alternative formulation.

Are biosimilars relevant to Duobrii?

No. Duobrii is a synthetic small-molecule topical combination, not a biologic. The relevant follow-on pathway is an ANDA or, depending on the product and regulatory strategy, another small-molecule application pathway rather than a biosimilar application under the Public Health Service Act.

References

Food and Drug Administration. (2019). FDA approves Duobrii lotion for plaque psoriasis. U.S. Department of Health and Human Services.
Food and Drug Administration. (2023a). Duobrii (halobetasol propionate and tazarotene) lotion: Prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book]. U.S. Department of Health and Human Services.
United States Patent No. 10,251,895. (2019). Topical pharmaceutical composition comprising halobetasol propionate and tazarotene. U.S. Patent and Trademark Office.
21 U.S.C. § 355. (2024). New drugs and antibiotics.
35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
Manual of Patent Examining Procedure § 2111. (U.S. Patent and Trademark Office, 2024). Claim interpretation; broadest reasonable interpretation.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	DUOBRII	halobetasol propionate; tazarotene	LOTION;TOPICAL	209354-001	Apr 25, 2019	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016279801	⤷ Start Trial
Brazil	112017027332	⤷ Start Trial
Brazil	112019023817	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,251,895

Which drugs does patent 10,251,895 protect, and when does it expire?

Summary for Patent: 10,251,895